{"id":8927,"date":"2020-08-10T12:04:23","date_gmt":"2020-08-10T19:04:23","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=8927"},"modified":"2021-04-12T12:05:07","modified_gmt":"2021-04-12T19:05:07","slug":"sars-cov-2-clearance-in-covid-19-patients-with-novaferon-treatment-a-randomized-open-label-parallel-group-trial","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2020\/08\/10\/sars-cov-2-clearance-in-covid-19-patients-with-novaferon-treatment-a-randomized-open-label-parallel-group-trial\/","title":{"rendered":"SARS-CoV-2 Clearance in COVID-19 Patients with\u00a0Novaferon\u00a0Treatment: A Randomized, Open-Label, Parallel Group Trial"},"content":{"rendered":"<ul>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"26\" data-aria-posinset=\"1\" data-aria-level=\"2\"><span data-contrast=\"auto\">Novaferon, a\u00a0<\/span><span data-contrast=\"auto\">medication<\/span><span data-contrast=\"auto\">\u00a0modeled after human interferons<\/span><span data-contrast=\"auto\">, effectively inhibited replication of cells infected with SARS-CoV-2 in a laboratory setting. Healthy cells that were incubated with the drug also resisted the entry of SARS-CoV-2.<\/span><span data-ccp-props=\"{&quot;134233279&quot;:true,&quot;201341983&quot;:0,&quot;335559685&quot;:360,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/li>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"26\" data-aria-posinset=\"2\" data-aria-level=\"2\"><span data-contrast=\"auto\">In a clinical trial,\u00a0<\/span><span data-contrast=\"auto\">patients with moderate to severe<\/span><span data-contrast=\"auto\">\u00a0<\/span><span data-contrast=\"auto\">COVID-19\u00a0<\/span><span data-contrast=\"auto\">(n=89)<\/span><span data-contrast=\"auto\">\u00a0randomized to receive\u00a0<\/span><span data-contrast=\"auto\">Novaferon\u00a0<\/span><span data-contrast=\"auto\">or<\/span><span data-contrast=\"auto\">\u00a0<\/span><span data-contrast=\"auto\">Novaferon\u00a0plus Lopinavir<\/span><span data-contrast=\"auto\">\/<\/span><span data-contrast=\"auto\">Ritonavir had significantly higher viral clearance rates on day 6 after treatment than patients treated with Lopinavir<\/span><span data-contrast=\"auto\">\/<\/span><span data-contrast=\"auto\">Ritonavir alone.\u00a0<\/span><span data-contrast=\"auto\">There was<\/span><span data-contrast=\"auto\">\u00a0<\/span><span data-contrast=\"auto\">no significant difference in viral clearance rates between the\u00a0Novaferon\u00a0group and the\u00a0Novaferon\u00a0plus Lopinavir<\/span><span data-contrast=\"auto\">\/<\/span><span data-contrast=\"auto\">Ritonavir group<\/span><span data-contrast=\"auto\">.<\/span><span data-contrast=\"auto\">\u00a0Median time to viral clearance were 6 days<\/span><span data-contrast=\"auto\">\u00a0for the\u00a0<\/span><span data-contrast=\"auto\">Novaferon<\/span><span data-contrast=\"auto\">\u00a0group<\/span><span data-contrast=\"auto\">, 6 days<\/span><span data-contrast=\"auto\">\u00a0for the\u00a0<\/span><span data-contrast=\"auto\">Novaferon<\/span><span data-contrast=\"auto\">\u00a0plus\u00a0<\/span><span data-contrast=\"auto\">Lopinavir<\/span><span data-contrast=\"auto\">\/<\/span><span data-contrast=\"auto\">Ritonavir<\/span><span data-contrast=\"auto\">\u00a0group<\/span><span data-contrast=\"auto\">, and 9 days for the\u00a0<\/span><span data-contrast=\"auto\">Lopinavir<\/span><span data-contrast=\"auto\">\/<\/span><span data-contrast=\"auto\">Ritonavir alone<\/span><span data-contrast=\"auto\">\u00a0group<\/span><span data-contrast=\"auto\">.<\/span><span data-contrast=\"auto\">\u00a0No severe adverse events were reported.<\/span><span data-ccp-props=\"{&quot;134233279&quot;:true,&quot;201341983&quot;:0,&quot;335559685&quot;:360,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/li>\n<\/ul>\n<p><i><span data-contrast=\"none\">Zheng et al. (Aug 2020). SARS-CoV-2 Clearance in COVID-19 Patients with\u00a0Novaferon\u00a0Treatment: A Randomized, Open-Label, Parallel Group Trial. International Journal of Infectious Diseases.\u00a0<\/span><\/i><a href=\"https:\/\/doi.org\/10.1016\/j.ijid.2020.07.053\"><span data-contrast=\"none\">https:\/\/doi.org\/10.1016\/j.ijid.2020.07.053<\/span><\/a><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559685&quot;:720,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Novaferon, a\u00a0medication\u00a0modeled after human interferons, effectively inhibited replication of cells infected with SARS-CoV-2 in a laboratory setting. Healthy cells that were incubated with the drug also resisted the entry of SARS-CoV-2.\u00a0 In a clinical trial,\u00a0patients with moderate to severe\u00a0COVID-19\u00a0(n=89)\u00a0randomized to receive\u00a0Novaferon\u00a0or\u00a0Novaferon\u00a0plus Lopinavir\/Ritonavir had significantly higher viral clearance rates on day 6 after treatment than patients&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2020\/08\/10\/sars-cov-2-clearance-in-covid-19-patients-with-novaferon-treatment-a-randomized-open-label-parallel-group-trial\/\">Read more<\/a><\/div>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[],"topic":[19],"class_list":["post-8927","post","type-post","status-publish","format-standard","hentry","category-article-summary","topic-testing-and-treatment"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/8927","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=8927"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/8927\/revisions"}],"predecessor-version":[{"id":8928,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/8927\/revisions\/8928"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=8927"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=8927"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=8927"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=8927"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}